Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEOS
Previous Symbol
CUSIPN/A
Phone972-408-1300
Debt
Debt-to-Equity RatioN/A
Current Ratio0.94
Quick Ratio0.84
Price-To-Earnings
Trailing P/E Ratio-0.79
Forward P/E Ratio-1.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.02 million
Price / Sales2.53
Cash FlowN/A
Price / CashN/A
Book Value($0.90) per share
Price / Book-2.37
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-133.46%
Return on Equity-586.25%
Return on Assets-62.51%
Miscellaneous
Employees138
Outstanding Shares29,680,000
Market Cap$72.70 million
OptionableOptionable
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics Inc (NASDAQ:NEOS) released its quarterly earnings data on Friday, November, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.03. The business had revenue of $12.50 million for the quarter, compared to analysts' expectations of $14.80 million. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 133.46%. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
4 equities research analysts have issued 1 year target prices for Neos Therapeutics' shares. Their predictions range from $6.00 to $20.00. On average, they anticipate Neos Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 463.4% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.
What is the consensus analysts' recommendation for Neos Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (11/14/2018)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month PT of $20 for NEOS shares. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think continued success with the sales of its key drugs (Adzenys XR-ODT, Cotempla XR- ODT and Adzenys ER) as well as pipeline advancements (NT-0400 and NT-0501) will drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher." (11/9/2018)
Has Neos Therapeutics been receiving favorable news coverage?
Press coverage about NEOS stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neos Therapeutics earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Catalyst Pharmaceuticals (CPRX), Aduro BioTech (ADRO), BIOFRONTERA AG/ADR (BFRA), Kadmon (KDMN), Avid Bioservices (CDMO), CELYAD SA/ADR (CYAD), Athersys (ATHX), Neptune Wellness Solutions (NEPT), Magenta Therapeutics (MGTA), BioDelivery Sciences International (BDSI), Syros Pharmaceuticals (SYRS), Arbutus Biopharma (ABUS), Strongbridge Biopharma (SBBP), Evelo Biosciences (EVLO) and Proteostasis Therapeutics (PTI).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Mr. Richard I. Eisenstadt, Chief Financial Officer (Age 60)
- Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
- Mr. Gerald W. McLaughlin, CEO & Director (Age 50)
- Mr. Russ McMahen, Sr. VP of R&D
- Dr. Carolyn R. Sikes Ph.D., VP of Clinical Affairs
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
Who are Neos Therapeutics' major shareholders?
Neos Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (8.40%), BlackRock Inc. (7.15%), Sphera Funds Management LTD. (2.80%), Russell Investments Group Ltd. (1.30%), Nexthera Capital LP (1.05%) and Essex Investment Management Co. LLC (0.96%). View Institutional Ownership Trends for Neos Therapeutics.
Which institutional investors are selling Neos Therapeutics stock?
Which institutional investors are buying Neos Therapeutics stock?
NEOS stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Stonepine Capital Management LLC, Franklin Resources Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Essex Investment Management Co. LLC, Bridgeway Capital Management Inc. and BlackRock Inc.. View Insider Buying and Selling for Neos Therapeutics.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $2.13.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $72.70 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.
What is Neos Therapeutics' official website?
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
